AI-Native Scoping Reviews & Evidence Mapping

Semaglutide is not just a weight-loss drug — this review maps how it reaches across obesity, diabetes, cardiovascular disease, kidney protection, liver disease, and emerging neurologic pathways, while separating strong evidence from hype. The full paper is worth reading because it shows where semaglutide truly delivers the biggest clinical gains, where the safety and durability limits begin, and which future uses may matter most.

This review shows that tattooing is far more than cosmetic ink: it maps how tattoos can act as long-term biological exposures linked to inflammation, pigment migration, diagnostic confusion, allergic disease, and possible cancer signals, while also serving as powerful medical tools in reconstruction, localization, drug delivery, and wearable sensing. The full paper is worth reading because it turns a scattered and emotionally charged topic into a clinically useful evidence map of where tattooing helps, where it harms, and which risks, technologies, and unanswered questions matter most.

This review shows where clopidogrel truly outperforms aspirin, where the advantage disappears, and why the answer changes across PCI, stroke, PAD, gastrointestinal risk, and surgery. It turns a common everyday antiplatelet choice into a clinically practical evidence map of who may benefit more from clopidogrel, when aspirin may still be safer, and where the real uncertainties remain.

This review shows that AAA diagnosis is no longer just about measuring diameter: the strongest evidence now points to a multimodal pathway where ultrasound and CTA remain the clinical backbone, while CEUS, biomechanical modeling, and emerging biomarker panels begin to refine who truly carries higher rupture or surveillance risk. The full paper maps where these newer tools already add real diagnostic value, where they remain premature, and how AAA detection is shifting from simple imaging toward biologically and mechanically informed precision assessment.

This review shows where AI is already delivering real value in drug discovery: not just faster predictions, but experimentally validated hits, better ADMET screening, large-scale virtual screening, and even early human translation. It maps which AI advances are truly credible, which claims remain fragile, and where the field is genuinely moving from hype to practical therapeutic impact.

This review shows that the strongest medication signal in AAA is not true aneurysm-shrinking therapy, but better survival: statins and antiplatelet treatment repeatedly track with lower long-term mortality, while most putative growth-modifying drugs still rest on mixed or observational evidence. It maps where medical AAA care is already actionable today, where metformin and other candidates remain uncertain, and which pharmacologic strategies may genuinely change aneurysm biology rather than just cardiovascular risk.

Research automation is no longer a futuristic add-on — this review shows where it is already transforming science, from trial recruitment and evidence synthesis to laboratory workflows and multimodal data pipelines, often cutting manual work by more than 90% without sacrificing performance. Across 1,679 original studies, the paper maps not only where automation truly delivers speed, scale, and reproducibility, but also where human oversight remains the difference between safe acceleration and costly over-trust.

Personalized healthcare is no longer just a promise of precision medicine — this review shows where it is already becoming clinically real, from AI prediction and pharmacogenomics to wearable monitoring and tailored care pathways. Across more than 1,300 original studies, the paper maps which personalized strategies are truly improving diagnosis, chronic disease control, and care delivery — and where the field still risks failing on fairness, infrastructure, and real-world implementation.

This review shows that rare vascular diseases are not just isolated curiosities: many are driven by shared pathways of vascular fragility, abnormal remodeling, and delayed diagnosis. It highlights where genetics, imaging, and targeted therapies are already turning rare vascular biology into practical clinical decisions.

This paper shows that prolonged fasting is not a single “healthy” or “harmful” phenomenon, but a powerful biological stressor that can trigger major systemic remodeling while producing very different clinical effects depending on duration, population, and context. It is worth reading because it maps where fasting may improve metabolism and perioperative care, where it may carry real risk, and how a broad, mixed literature can be turned into a clinically usable evidence landscape.

WIfI combines true biological risk signals such as ischemia with limb-level consequences such as wound burden and infection to answer the central clinical question in PAD: is limb salvage still realistically achievable? This evidence map shows how WIfI stage translates into real-world amputation risk across clinical scenarios, and where its predictive value becomes strongest in modern decision-making.